Previous 10 | Next 10 |
home / stock / drug:cc / drug:cc news
— Presentation entitled "BMB-101: A selective 5-HT 2C agonist in clinical trials with therapeutic utility" — — First-in-human Phase 1 trial for lead program, BMB-101, is underway in Australia — VANCOUVER, British Columbia, April 10, 20...
-- First-in-human Phase 1 trial for lead program, BMB-101, a highly selective 5-HT 2C agonist, is underway in Australia -- -- Company has transitioned from a discovery to a development organization – -- Company to attend BIO-Europe Spring Conference in Basel, Switzerland, Mar...
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES VANCOUVER, British Columbia, Feb. 17, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASD...
VANCOUVER, British Columbia, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (“ Bright Minds ” or the “ Company ”) announces that it has received a letter (the “ Deficiency Letter ”) from the Nasdaq Sto...
VANCOUVER, British Columbia, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (“ Bright Minds ” or the “ Company ”) announces that it has received a notification letter (the “ Notification Letter ”) from...
VANCOUVER, British Columbia, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsych...
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, British Columbia, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:...
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, British Columbia, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (N...
-- Dr. Smith is a 20-year pharmaceutical industry veteran with extensive central nervous system (“CNS”) clinical development expertise -- VANCOUVER, British Columbia, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB...
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – October 5, 2022 – A new study undertaken by experts at John Hopkins University School of Medicine has revealed that taking psychedelics can have the same transformational effec...
News, Short Squeeze, Breakout and More Instantly...
Bright Minds Biosciences Inc. Company Name:
DRUG:CC Stock Symbol:
CNQC Market:
Bright Minds Biosciences Inc. Website:
A look at the top 10 most actives in Canada Ivanhoe Mines Ltd. (IVN) fell 9.6% to $18.64 on volume of 19,471,224 shares Canopy Growth Corporation (WEED) rose 78.2% to $20.24 on volume of 19,456,911 shares Enbridge Inc. (ENB) fell 0.4% to $48.95 on volume of 18,616,928 shares Tilray Bran...
A look at the top 10 most actives in Canada Auxly Cannabis Group Inc. (XLY) rose 100.0% to $0.06 on volume of 25,275,816 shares Canopy Growth Corporation (WEED) rose 15.2% to $9.8 on volume of 18,760,847 shares Toronto-Dominion Bank (The) (TD) rose 0.1% to $81.04 on volume of 18,116,348 s...
Bright Minds Announces Non-Brokered Private Placement Fully Subscribed by Management Canada NewsWire /NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITE...